PMID- 34547284
OWN - NLM
STAT- MEDLINE
DCOM- 20220422
LR  - 20220422
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 363
IP  - 3
DP  - 2022 Mar
TI  - The Association of Thyroid Hormones With Cardiogenic Shock and Prognosis in 
      Patients with ST Segment Elevation Myocardial Infarction (STEMI) Treated with 
      Primary PCI.
PG  - 251-258
LID - S0002-9629(21)00315-3 [pii]
LID - 10.1016/j.amjms.2021.06.020 [doi]
AB  - BACKGROUND: Cardiogenic shock (CS) is the leading cause of the death in patients 
      with ST elevation myocardial infarction (STEMI). Thyroid dysfunction is related 
      to prognosis of patients with myocardial infarction. Hence, the aim of this study 
      is to explore the relationship between thyroid hormones (free triiodothyronine 
      [FT3] and free thyroxine [FT4]) and CS. METHODS: A total of 1270 patients with 
      STEMI treated with percutaneous coronary intervention (PCI) were consecutively 
      enrolled in our study. Patients were classified into two groups according to with 
      or without CS during hospitalization. Stepwise multivariate logistic analysis was 
      conducted to investigate the association of thyroid hormones and CS. Restricted 
      cubic spline method was employed to further explore the relationship between CS 
      and thyroid hormones. RESULTS: Patients who developed CS (n=103) had lower FT3 
      and higher FT4 upon admission. The stepwise logistic analysis showed both FT3 
      (P=0.038) and FT4 (P=0.024) were independently related to CS. Restricted cubic 
      splines indicated that lower FT3 (<2.25 pg/ml) or higher FT4 (>1.25 ng/dl) were 
      correlated with higher prevalence of CS. Over 2.5 years' follow-up, patients 
      (n=294) with low FT3 (<2.85 pg/ml) and high FT4 (>=0.88 ng/dl) had the highest 
      all-cause mortality (18.2%), whereas patients (n=293) with high FT3 and low FT4 
      had the lowest all-cause mortality (3.8%) (P for trend <0.0001). CONCLUSIONS: 
      Both FT3 and FT4 were independently associated with in-hospital CS development in 
      patients with STEMI treated with PCI. Patients with lower range of FT3 and upper 
      range of FT4 had the worst outcomes in long-term follow-up.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Xue, Yuzhou
AU  - Xue Y
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhu, Yuansong
AU  - Zhu Y
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Shen, Jian
AU  - Shen J
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Xiang, Jing
AU  - Xiang J
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Xiang, Zhenxian
AU  - Xiang Z
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Wang, Linbang
AU  - Wang L
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Luo, Suxin
AU  - Luo S
AD  - Department of Cardiology, the First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China. Electronic address: luosuxin0204@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210920
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 06LU7C9H1V (Triiodothyronine)
SB  - IM
MH  - Humans
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Prognosis
MH  - *ST Elevation Myocardial Infarction/complications/surgery
MH  - Shock, Cardiogenic/epidemiology/etiology/therapy
MH  - Triiodothyronine
OTO - NOTNLM
OT  - Cardiogenic shock
OT  - ST elevation myocardial infarction (STEMI)
OT  - Thyroid hormone
OT  - Thyroxine
OT  - Triiodothyronine
EDAT- 2021/09/22 06:00
MHDA- 2022/04/23 06:00
CRDT- 2021/09/21 20:13
PHST- 2020/07/29 00:00 [received]
PHST- 2021/03/02 00:00 [revised]
PHST- 2021/06/02 00:00 [accepted]
PHST- 2021/09/22 06:00 [pubmed]
PHST- 2022/04/23 06:00 [medline]
PHST- 2021/09/21 20:13 [entrez]
AID - S0002-9629(21)00315-3 [pii]
AID - 10.1016/j.amjms.2021.06.020 [doi]
PST - ppublish
SO  - Am J Med Sci. 2022 Mar;363(3):251-258. doi: 10.1016/j.amjms.2021.06.020. Epub 
      2021 Sep 20.